ReNeuron’s clinical data presentation at last month’s American Academy of Ophthalmology (AAO) meeting was met with some stock price weakness. The first 8 out of a total of 22 patients in the Phase I/IIa study included a 180-day update on the three patients initially reported in February where startling vision gains were reported. The first 12 patients in the Phase I study portion will now be followed for safety only. Two recently-dosed patients experienced some procedure-related v
19 Nov 2019
Now the dust has settled
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Now the dust has settled
ReNeuron Group plc (RENE:LON) | 3.0 0 0.0% | Mkt Cap: 1.74m
- Published:
19 Nov 2019 -
Author:
Andy Smith -
Pages:
2
ReNeuron’s clinical data presentation at last month’s American Academy of Ophthalmology (AAO) meeting was met with some stock price weakness. The first 8 out of a total of 22 patients in the Phase I/IIa study included a 180-day update on the three patients initially reported in February where startling vision gains were reported. The first 12 patients in the Phase I study portion will now be followed for safety only. Two recently-dosed patients experienced some procedure-related v